These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27860066)

  • 1. CRISPR/Cas9, a powerful tool to target human herpesviruses.
    van Diemen FR; Lebbink RJ
    Cell Microbiol; 2017 Feb; 19(2):. PubMed ID: 27860066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections.
    van Diemen FR; Kruse EM; Hooykaas MJ; Bruggeling CE; Schürch AC; van Ham PM; Imhof SM; Nijhuis M; Wiertz EJ; Lebbink RJ
    PLoS Pathog; 2016 Jun; 12(6):e1005701. PubMed ID: 27362483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Application of the CRISPR/Cas9 System against Herpesvirus Infections.
    Chen YC; Sheng J; Trang P; Liu F
    Viruses; 2018 May; 10(6):. PubMed ID: 29844277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenesis and Genome Engineering of Epstein-Barr Virus in Cultured Human Cells by CRISPR/Cas9.
    Yuen KS; Chan CP; Kok KH; Jin DY
    Methods Mol Biol; 2017; 1498():23-31. PubMed ID: 27709566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The application of CRISPR-Cas9 gene editing technology in viral infection diseases].
    Yin LJ; Hu SQ; Guo F
    Yi Chuan; 2015 May; 37(5):412-8. PubMed ID: 25998428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-The ultimate weapon to battle infectious diseases?
    Doerflinger M; Forsyth W; Ebert G; Pellegrini M; Herold MJ
    Cell Microbiol; 2017 Feb; 19(2):. PubMed ID: 27860197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Genome Editing Approaches against Herpes Simplex Virus Infections.
    Zhang I; Hsiao Z; Liu F
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33671590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential application and challenge of powerful CRISPR/Cas9 system in cardiovascular research.
    Li Y; Song YH; Liu B; Yu XY
    Int J Cardiol; 2017 Jan; 227():191-193. PubMed ID: 27847153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome modification by CRISPR/Cas9.
    Ma Y; Zhang L; Huang X
    FEBS J; 2014 Dec; 281(23):5186-93. PubMed ID: 25315507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection].
    Han Y; Li QW
    Yi Chuan; 2016 Jan; 38(1):9-16. PubMed ID: 26787519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune modulation during latent herpesvirus infection.
    White DW; Suzanne Beard R; Barton ES
    Immunol Rev; 2012 Jan; 245(1):189-208. PubMed ID: 22168421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of CRISPR/Cas9 mediated genome editing in farm animals].
    Xing YY; Yang Q; Ren J
    Yi Chuan; 2016 Mar; 38(3):217-26. PubMed ID: 27001476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of cellular metabolism during latent Kaposi's Sarcoma herpesvirus infection.
    Lagunoff M
    Curr Opin Virol; 2016 Aug; 19():45-9. PubMed ID: 27434732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Herpesviruses survival strategies--latency and apoptosis].
    Miszczak D; Słońska A; Golke A; Cymerys J
    Postepy Hig Med Dosw (Online); 2013 Apr; 67():276-87. PubMed ID: 23619227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete and Prolonged Inhibition of Herpes Simplex Virus Type 1 Infection In Vitro by CRISPR/Cas9 and CRISPR/CasX Systems.
    Karpov DS; Demidova NA; Kulagin KA; Shuvalova AI; Kovalev MA; Simonov RA; Karpov VL; Snezhkina AV; Kudryavtseva AV; Klimova RR; Kushch AA
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
    Zhu W; Lei R; Le Duff Y; Li J; Guo F; Wainberg MA; Liang C
    Retrovirology; 2015 Feb; 12():22. PubMed ID: 25808449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.